CCR has established a unique and exciting partnership with Beckton Dickinson (BD) Pharmingen to produce mouse monoclonal antibodies against key cancer targets of interest to CCR - at no cost to individual investigators. A list of antigens is now being compiled that includes: (1) novel candidate proteins for which no commercially available antibodies exist; (2) known proteins for which commercially available antibodies exist but fail to meet investigators' requirements; and (3) proteins with phosphorylation sites that may be of importance in activation pathways. Proposals submitted by CCR PI’s will be reviewed and prioritized by a committee consisting of CCR and BD-Pharmingen scientists.

Dr. Paul K. Goldsmith (paulg@mail.nih.gov), head of the Antibody and Protein Purification Unit (APPU), will provide principal investigators with assistance in producing peptide-specific antibodies. The laboratory will also assist investigators in using these antibodies in immunoassays and other techniques for protein purification and characterization.

Dr. Mark Raffeld (mraff@box-m.nih.gov) chief of the Clinical Immunohistochemistry Lab in LP, CCR will assist investigators in the characterization of the new antibodies for their reactivity in tissue.

For more information on this unique opportunity, please contact:

Shoshana Segal, Ph.D.
E-mail: shosh@nih.gov
Telephone: 301-496-0923
Assistant Director for Technology Development
Office of Science and Technology Partnerships
Office of the Director, CCR